Novonesis (Novozymes) B (FRA:NZM) Total Equity: €10,920 Mil (As of Mar. 2026)


FRA:NZM Novonesis (Novozymes) B FRA:NZM
90 GF Score
Price €54.50
GF Value €55.83
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Total Equity?

Novonesis (Novozymes) B FRA:NZM -3.54% 90 Total Equity is €10,920 Mil as of Mar. 2026. GuruFocus rates FRA:NZM with a GF Score™ of 90/100 and a GF Value™ of €55.83 (Fairly Valued). The stock has 6 warning signs investors should review.

Novonesis (Novozymes) B's total equity for the quarter that ended in Mar. 2026 was €10,920 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Novonesis (Novozymes) B Total Equity Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Total Equity Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,641.19 1,909.57 1,925.60 11,176.00 10,855.20

Novonesis (Novozymes) B Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,230.70 10,742.90 10,744.10 10,855.20 10,919.60
FRA:NZM
90GF Score
Novonesis (Novozymes) B FRA:NZM
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Novonesis (Novozymes) B's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=16349.1-5493.9
=10,855

Novonesis (Novozymes) B's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=16523.3-5603.7
=10,920

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €10,920 Mil mean?
Novonesis (Novozymes) B (FRA:NZM) has a Total Equity of €10,920 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's Total Equity too high?
Novonesis (Novozymes) B's current Total Equity is €10,920 Mil. Overall, Novonesis (Novozymes) B has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Total Equity compare to LIN and SHW?
Novonesis (Novozymes) B's Total Equity of €10,920 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Chemicals company?
A good Total Equity depends on the Chemicals industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current Total Equity is €10,920 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (FRA:NZM) is currently considered Fairly Valued. The stock's GF Value™ is €55.83, compared to a current price of €54.50 — trading 2.4% below its estimated fair value. The current Total Equity is €10,920 Mil. Novonesis (Novozymes) B's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Novonesis (Novozymes) B (FRA:NZM), the current Total Equity is €10,920 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (FRA:NZM) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued. The current stock price of €54.50 is trading 2.4% below its estimated GF Value™ of €55.83. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for FRA:NZM:

  • Total Equity: €10,920 Mil
  • GF Value™: €55.83 vs. price of €54.50 (2.4% below fair value)
  • GF Score™: 90/100 with 6 warning signs

No single metric tells the full story. See the FRA:NZM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
90GF Score

Get the complete analysis for FRA:NZM

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€54.50
Price
€55.83
GF Value